Posts tagged CKD
Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More
Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200.

Read More
Stifel starts Reata Pharma at buy

Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22.

Read More
Maxim upgrades Keryx to buy

Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “hold” and reinstated its $7 price target after the FDA approved its application for a second contract manufacturer of Auryxia for the control of serum phosphorus levels in patients with CKD on dialysis.

Shares of Keryx were changing hands at $5.35, up 56 cents, in afternoon trading on Wednesday.

Read More